Cytori Cell Therapy Phase I Trial Reports Maxillofacial Bone Regeneration

(RTTNews) - Cytori Therapeutics Inc. (CYTX) said it has published the results from an investigator-initiated Phase I trial using Cytori Cell Therapy in patients with insufficient maxillary bone prior to dental implantation.

The publication reported approximately 42 percent greater bone formation in maxillary sinus floor elevation or MSFE procedures treated with cells in combination with scaffolds, versus those that received scaffold alone.

The study, conducted by investigators from Departments of Orthopedic Surgery, Oral and Maxillofacial Surgery, and Oral Cell Biology of the VU University in Amsterdam, The Netherlands, enrolled 10 patients requiring dental implants but who had insufficient bone into which the implant could be inserted.

The maxillary bone deficiency was treated with two different commonly-used, off-the-shelf bone calcium phosphate scaffolds that were used either alone or pre-loaded with Adipose-Derived Regenerative Cells or ADRCs prepared using Cytori's Celution System.

Six months after treatment all patients underwent dental implant placement at which time a biopsy of the regenerated bone at the graft site was performed. The trial results reported approximately 42 percent greater bone formation in grafts that were supplemented with ADRCs.